La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Betta Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Lieming Ding

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	11yrs
Proprietà del CEO	0.2%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	4.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 07

Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares

Jul 30

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Jul 05

Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Apr 26

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Apr 23

What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Apr 16

AMMINISTRATORE DELEGATO

Lieming Ding (61 yo)

11yrs

Mandato

CN¥2,955,800

Compensazione

Dr. Lieming Ding founded Betta Pharmaceuticals Co., Ltd.(also known as Zhejiang BetaPharma Co., Ltd) in 2002 and serves as its Chairman. Dr. Ding has been Chief Executive Officer and General Manager of Bet...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Lieming Ding	Founder	no data	CN¥2.96m	0.24% CN¥ 33.2m
Jianxun Fan	VP, CFO & Director	no data	CN¥1.36m	0.031% CN¥ 4.4m
Jiang Wan	Senior VP	4.8yrs	CN¥2.56m	0.025% CN¥ 3.5m
Jiabing Wang	Senior VP	4.8yrs	CN¥2.58m	0.047% CN¥ 6.6m
Jia Tong	Director	no data	CN¥1.35m	0.039% CN¥ 5.5m
Wei Wang	Independent Director	4.8yrs	CN¥120.00k	Nessun dato
Cai Jiangnan	Independent Director	4.8yrs	CN¥120.00k	Nessun dato
Yangnan Zhang	Chairman of the Supervisory Board & Senior Director of Project Declaration	4.8yrs	Nessun dato	Nessun dato
Zhihua Yu	Director	4.8yrs	Nessun dato	Nessun dato
Tian Xu	Director	1.8yrs	Nessun dato	Nessun dato
Fei Wu	Supervisor	no data	Nessun dato	Nessun dato
Jiajia Xiao	Independent Director	1.8yrs	CN¥25.10k	Nessun dato

4.8yrs

Durata media

56.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 300558 sono considerati esperti (durata media dell'incarico 4.8 anni).

Betta Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024

Betta Pharmaceuticals Co., Ltd. Approves Board Elections

Insufficient new directors

High number of new and inexperienced directors

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 28, 2022

Recent updates

Consensus EPS estimates increase by 15%, revenue downgraded

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

New minor risk - Earnings quality

Second quarter 2024 earnings: EPS exceeds analyst expectations

Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Betta Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 06, 2024

Dividend increased to CN¥0.17

Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares as Cash Dividend (Tax Included) for the Year 2023, Payable on 06 June 2024

Consensus EPS estimates fall by 17%

Price target decreased by 9.5% to CN¥51.64

Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Consensus EPS estimates increase by 20%, revenue downgraded

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Price target increased by 12% to CN¥65.00

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Betta Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 18%

Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Consensus EPS estimates increase by 12%, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Betta Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Consensus EPS estimates fall by 13%

Price target decreased by 16% to CN¥57.04

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023

Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022

Price target increased by 13% to CN¥50.59

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Betta Pharmaceuticals Co., Ltd. Approves Board Elections

Insufficient new directors

Consensus revenue estimates fall by 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 11%

Price target decreased to CN¥57.39

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Betta Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 999.999991 million in funding

Investor sentiment improved over the past week

Betta Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Payable on 30 May 2022

High number of new and inexperienced directors

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 28, 2022

Betta Pharmaceuticals Co., Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Price target decreased to CN¥117

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.92 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.033 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.36 (vs CN¥0.33 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.50 (vs CN¥0.58 in FY 2019)

New 90-day low: CN¥95.46

Investor sentiment deteriorated over the past week

Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

Analysts update estimates

Price target raised to CN¥97.57

New 90-day high: CN¥120

Market pulls back on stock over the past week

New 90-day low: CN¥99.80

Analysts update estimates

Third-quarter earnings released: Revenue and earnings beat expectations

Third quarter earnings released

New 90-day low: CN¥108

Analysts update estimates

New 90-day low - CN¥110

Ningbo Kaiming Innovation Technology Co., Ltd. completed the acquisition of Zhejiang Betta Pharmaceutical Technology Co., Ltd. from Betta Pharmaceuticals Co., Ltd. (SZSE:300558).

Earnings released